SAN DIEGO, Feb. 13 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. , a biopharmaceutical company developing and commercializing recombinant human enzymes, announced today that the US Patent Trademark Office has given a notice of allowance to both natural and recombinant forms of HTI-101, a second enzyme in Halozyme's pipeline. The patent is licensed exclusively to Halozyme from the University of California, San Francisco. The new patent claims for HTI-101 are directed to a human enzyme normally found in the bloodstream with a mechanism of action that is distinct from Halozyme's FDA approved rHuPH20 enzyme. This new enzyme may prove useful for additional therapeutic applications. Halozyme is currently conducting pre-clinical work with HTI-101 in the fields of oncology and inflammation.
"We are pleased to add these new natural and recombinant composition of matter claims in the '283 patent to Halozyme's growing human enzyme intellectual property estate," said Gregory Frost, PhD, Halozyme's Chief Scientific Officer. "This second enzyme can be readily channeled into our commercially validated molecular engineering systems and mammalian manufacturing processes, and fits nicely with Halozyme's demonstrated ability to develop and commercialize recombinant human enzymes."
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing recombinant human enzymes for the infertility, palliative care, and oncology markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. Halozyme's recombinant human enzymes may replace current animal slaughterhouse-derived extracts that carry potential risks of animal pathogen transmission and immunogenicity. The company has received FDA approval for two products: Cumulase(TM), the first and only recombinant human hyaluronidase for cumulus removal in the IVF process; and Hylenex(TM), for use as an adjuvant to increase the absorption and dispersion of other injected drugs. The versatility of the first enzyme, rHuPH20, enables Halozyme to develop the product as a medical device, drug enhancement agent, and therapeutic drug.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning pre-clinical data, the potential effectiveness of products under development, the potential application to additional therapeutic areas, and the ability to develop and commercialize recombinant human enzymes) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-KSB, 10-QSB and other filings with the Securities and Exchange Commission.
Halozyme Contact Investor Relations Contact David A. Ramsay Zachary Bryant Chief Financial Officer Lippert/Heilshorn & Associates (858) 794-8889 (310) 691-7100 dramsay@halozyme.comzbryant@lhai.com Media Contacts Kathy Sweeney / Joleen Schultz Mentus (858) 455-5500, x230/x215 kwitz@mentus.comjschultz@mentus.com
Halozyme Therapeutics, Inc.CONTACT: David A. Ramsay, Chief Financial Officer of HalozymeTherapeutics, Inc., +1-858-794-8889, dramsay@halozyme.com; or Investors,Zachary Bryant of Lippert/Heilshorn & Associates, +1-310-691-7100,zbryant@lhai.com, for Halozyme Therapeutics, Inc.; or Media, Kathy Sweeney,kwitz@mentus.com, ext. 230, or Joleen Schultz, jschultz@mentus.com, ext.215, both of Mentus, +1-858-455-5500, for Halozyme Therapeutics, Inc.
Web site: http://www.halozyme.com//
